Subcutaneous

Subcutaneous describes the anatomical layer beneath the skin and above muscle, serving as an administration site for injectable medicines offering advantages including ease of self-administration, reduced injection pain compared with intramuscular routes, and sustained absorption enabling depot formulations. This delivery route accommodates volumes typically up to 1.5 millilitres, enabling administration of biologics, vaccines, insulin, and other therapeutics requiring parenteral delivery but not immediate systemic exposure.

The pharmaceutical industry increasingly develops subcutaneous formulations, particularly for biologics, enabling convenient self-administration and improving patient adherence compared with intravenous infusions requiring healthcare facility visits. Therapeutic proteins including monoclonal antibodies traditionally administered intravenously now have subcutaneous alternatives through high-concentration formulations, co-formulation with hyaluronidase enhancing dispersion, or delivery devices enabling larger volumes. Absorption from subcutaneous tissue occurs through lymphatic and blood capillaries, with large molecules such as antibodies absorbing primarily through lymphatics with bioavailability ranging from 50% to 100%. Formulation challenges include achieving high concentrations without excessive viscosity, maintaining stability, and minimising injection site reactions. Delivery devices include autoinjectors, pre-filled syringes, and wearable pumps. As patient-centred care emphasises convenience and biologic development pipelines grow, subcutaneous administration continues expanding enabling home-based therapy supporting improved quality of life.